Literature DB >> 7542793

Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.

Q Su1, L Weber, M Le Hir, G Zenke, B Ryffel.   

Abstract

Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of CsA and FK506 toxicity were investigated. Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract. In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin. Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin. These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542793     DOI: 10.1159/000173910

Source DB:  PubMed          Journal:  Ren Physiol Biochem        ISSN: 1011-6524


  9 in total

1.  FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Nathalie Ubrich; Hirofumi Takeuchi; Philippe Maincent; Yoshiaki Kawashima
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

2.  NFATc2 Modulates Microglial Activation in the AβPP/PS1 Mouse Model of Alzheimer's Disease.

Authors:  Gunjan D Manocha; Atreyi Ghatak; Kendra L Puig; Susan D Kraner; Christopher M Norris; Colin K Combs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

4.  Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.

Authors:  S D Lytton; U Berg; A Nemeth; M Ingelman-Sundberg
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

5.  LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.

Authors:  Matthew A Cunningham; Bobbie Ann Austin; Zhuqing Li; Baoying Liu; Steven Yeh; Chi-Chao Chan; Eddy Anglade; Poonam Velagaleti; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

6.  Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation.

Authors:  Cyrus Jahansouz; Cameron Jahansouz; Sean C Kumer; Kenneth L Brayman
Journal:  J Transplant       Date:  2011-10-15

7.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

8.  Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition.

Authors:  Lalida Rojanathammanee; Angela M Floden; Gunjan D Manocha; Colin K Combs
Journal:  J Neuroinflammation       Date:  2015-03-04       Impact factor: 8.322

9.  Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay.

Authors:  Jian Li; Jing Chen; Chunshan Gui; Li Zhang; Yu Qin; Qiang Xu; Jian Zhang; Hong Liu; Xu Shen; Hualiang Jiang
Journal:  Bioorg Med Chem       Date:  2005-11-22       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.